According to Dr Roopinder Sandu (Smidt Heart Institute, CA, USA) and co-investigators, the options for predicting SCD in patients with CAD and an ejection fraction above 35% are limited, notwithstanding that SCD frequently occurs in this population. Therefore, the research team analysed genome-wide genotyping of 4,698 patients who were enrolled in the PRE-DETERMINE study to develop a genome-wide polygenic score for patients with CAD. The primary endpoint was sudden arrhythmic death.
The results showed that patients in the top decile of the polygenic score for CAD had a higher absolute (8% vs 4%; P=0.005) and proportional (29% vs 16%; P=0.0003) risk for sudden arrhythmic death than patients in any other decile. The effect was driven by SCD events (HR 1.77; 95% CI 1.23-2.54; P=0.002) but not by non-sudden arrhythmic death events (HR 1.00; 95% CI 0.8-1.25; P=0.98). These findings were consistent across left ventricular ejection fractions, ECG parameters, and clinical factors. According to the authors, the polygenic risk score for CAD is promising as a screening tool, but it needs to be established whether it predicts recurrent ischaemia or ventricular fibrillation. If it actually predicts ventricular fibrillation, the tool could help inform clinicians whether or not patients would benefit from an ICD. A randomised controlled trial is needed to solve this issue.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Abnormal cardiac ATP may predict SCD Next Article
Signs of heart disease may be more subtle in women than in men »
« Abnormal cardiac ATP may predict SCD Next Article
Signs of heart disease may be more subtle in women than in men »
Related Articles
February 23, 2021
Dapagliflozin could rapidly curb worsening heart failure, death
January 20, 2022
People with HIV at higher risk of heart failure
September 22, 2020
Non-physicians may optimize heart failure drugs remotely
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com